End-of-Lif

End-of-Life Cancer Care More Aggressive for Patients With Defibrillators

Patients with advanced cancer who also had implantable cardioverter defibrillators (ICDs) were more likely than those without ICDs to receive aggressive end-of-life care, according to a study published in the journal Cancer.  The findings could help physicians guide patients in this growing population toward care that better matches their goals. “We know that many people who have cancer are also dealing with other medical problems concurrently, including heart arrhythmias,” said Megan A. Mullins, PhD, University of Texas Southwestern Medical Center, Dallas, Texas. “By putting these heart...

Patients With Heart Disease May Be at Increased Risk for Advanced Breast Cancer

A case-control study of 19,292 individuals found that patients with more advanced breast cancer at diagnosis had a statistically significant 10% increased odds of prevalent cardiovascular disease, even when accounting for factors associated with dela...

Paracetamol May Not Be as Safe as Perceived in Older People

Repeated doses of paracetamol in people aged 65 years and older, can lead to an increased risk of gastrointestinal, cardiovascular, and renal complications, according to a study published in the journal Arthritis Care and Research. The finding emp...


Sixty Seconds Science


Spotify episodes

Apple podcasts

Google podcasts

Partner

Search:
Date
Filters:
Highligths
27:34

Highligths of SABCS 2024

Presenter: Kate Lathrop
Oncology : Breast Cancer
SABCS 2024
CLL Highli
10:43

CLL Highlights from ASH 2024

Presenter: William G Wierda
Hematology
ASH 2024
Early Brea
12:56

Early Breast Cancer Updates

Presenter: Janice Tsang
Oncology : Breast Cancer
SABCS 2024
Mastering
9:21

Mastering the Art of Myelofibrosis Care: Expert Guidance, Clinical Experience, & Innovation for More Personalized Disease Control

Presenter: Francesco Passamonti
Hematology
ASH 2024
State of t
8:20

State of the Art Treatment in Lymphoma

Presenter: Catherine Diefenbach
Hematology
ASH 2024
State of t
7:55

State of the Art Treatment in Adult ALL

Presenter: Anand Patel
Hematology
ASH 2024
Crafting C
6:15

Crafting Custom Care in CLL: Guidance on Upfront and Sequential Treatment Decisions With Targeted and Immune-base Platforms

Presenter: Matthew S. Davids
Hematology
ASH 2024
Bridging G
3:57

Bridging Gaps in Multiple Myeloma Care: A Community Oncologist's Guide to Navigating the Evolving Treatment Landscape

Presenter: Rahul Banerjee
Hematology
ASH 2024
24-hour Ur
3:46

24-hour Urine Testing does not Add Value to Multiple Myeloma Response Assessments

Presenter: Rahul Banerjee
Hematology
ASH 2024
Do GLP-1s
2:11

Do GLP-1s Lower VTE Risk in People With Type 2 Diabetes?

Presenter: Cho Han Chiang
Hematology
ASH 2024
State of t
3:30

State of the Art Treatment in Myelofibrosis

Presenter: Aaron T. Gerds
Hematology
ASH 2024
State of t
2:45

State of the Art Treatment in Polycythemia Vera

Presenter: Aaron T. Gerds
Hematology
ASH 2024
The Aymara
9:56

The Aymara Gene: A Tale of High Altitude and Human Evolution

Presenter: Josef T. Prchal
Hematology
ASH 2024
Escape the
5:27

Escape the Amyloid Maze: Unraveling Data and Care Strategies for AL Amyloidosis

Presenter: Suzanne Lentzsch
Hematology
ASH 2024
Fixed-Dura
7:23

Fixed-Duration Acalabrutinib/Venetoclax in Fit Patients With CLL: AMPLIFY Trial

Presenter: Jennifer R. Brown
Hematology
ASH 2024
High-Fiber
5:49

High-Fiber NUTRIVENTION Study for Delaying Progression of Myeloma

Presenter: Urvi A. Shah
Hematology
ASH 2024
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease: Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
Cardiology
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
Cardiology
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
Cardiology
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
Cardiology
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
Cardiology
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients

Presenter: Andreas Goette
Cardiology
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Cardiology
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
Cardiology
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
Cardiology
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Cardiology
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
Cardiology
The import
11:22

The importance of the anterior interface in eye surgery

Presenter: Marie-José Tassignon
Internal Medicine
Haematolog
17:26

Haematology is at the forefront - interview with EHA President

Presenter: Antonio Almeida
Oncology
Overall Su
13:30

Overall Survival Results of KEYNOTE-564

Presenter: Stefan N. Symeonides
Oncology
General as
1:18

General aspects of the ESH2023 Hypertension Guidelines - What are the major changes?

Presenter: Michel Burnier
Cardiology
How shall
1:23

How shall be treat hypertension and look at cardiac risk factors when we consider proper treatment?

Presenter: Konstantinos Tsioufis
Cardiology
How to tre
1:06

How to treat patients optimally with chronic coronary syndromes in 2023?

Presenter: Luis Henrique Gowdak
Overall Su
20:13

Overall Survival Results of KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma

Presenter: David F. McDermott
Oncology
How novel
1:07

How novel AI model may help physicians distinguish and identify prefibrotic primary myelofibrosis from essential thrombocythemia?

Presenter: Andrew Srisuwananukorn
Hematology
The future
1:10

The future of Multiple Myeloma management

Presenter: Xavier Leleu
Hematology
Benefits o
1:01

Benefits of myeloma regimens in the real world fall well short of trials

Presenter: Alissa Visram
Hematology
The prefer
0:57

The preferred treatment of hypertension with RAAS blockade inhibitors

Presenter: Martin Strauss
Cardiology
What clini
1:16

What clinicians should know about the new ESH guideline regarding hypertension in women?

Presenter: Renata Cifkova
Cardiology
How to man
1:00

How to manage isolated systolic hypertension in the young?

Presenter: Paolo Palatini
Cardiology
Blood pres
1:34

Blood pressure monitoring in general and what we can do to encourage people.

Presenter: Neil Poulter
Cardiology
How to man
1:08

How to manage masked and masked uncontrolled hypertension?

Presenter: Paolo Palatini
Cardiology
ESMO 2023
1:13

ESMO 2023 Scientific Chair's welcome and invitation to next year's ESMO Congress

Presenter: Silke Gillessen
Oncology